Moolec Science Expands into Renewable Energy Following Record Agricultural Yields

Moolec Science Expands into Renewable Energy Following Record Agricultural Yields

2026-04-29 companies

London, Wednesday, 29 April 2026.
Following a record 2025 harvest that validated a 45% functional lipid concentration, Moolec Science is scaling its 2026 operations to expand into high-performance renewable energy feedstocks.

Scaling Safflower Production for Commercial Viability

Moolec Science SA (NASDAQ: MLEC) has successfully concluded the initial industrialization phase of its GLASO1 safflower platform [1]. The milestone follows a highly successful 2025 agricultural campaign that materially exceeded the company’s internal forecasts [1]. During this period, Moolec validated a gamma-linolenic acid (GLA) concentration of approximately 45% at commercial scale [1]. This high-yield output has enabled the company to coordinate large-scale harvesting and logistics, successfully integrating the raw biomass with downstream industrial processes to produce a ready-for-delivery end product [1].

Strategic Sowing and Genetic Optimization

Looking immediately ahead from today, April 29, 2026, Moolec is preparing for its 2026 GLASO1 campaign, with sowing scheduled to commence in early May 2026 across established agricultural infrastructure in the United States [1]. This execution-led scaling strategy is bolstered by a previously disclosed research collaboration with a major global agribusiness [1]. Through this partnership, Moolec has accessed a vast germplasm library containing 386 distinct safflower varieties sourced from Australia [1]. The company is currently in the final stages of selecting the optimal candidate varieties based on adaptability, performance, and industrial potential [1].

Market Position and Intellectual Property

This operational expansion comes after a period of regulatory navigation for the publicly traded company. Throughout 2024 and 2025, Moolec faced listing qualification challenges on the Nasdaq, including a bid price letter in September 2024 and a subsequent staff determination letter in March 2025 [2]. However, the company successfully regained Nasdaq compliance by June 11, 2025, stabilizing its market presence before receiving another determination letter in late November 2025 [2]. Despite these market fluctuations, the underlying business operations continue to expand across the United States, Europe, and South America [1].

Sources


Biotechnology Moolec Science